Daniel Eli Hoenich Bach

Daniel represents individuals, asset managers and pension funds in complex securities, consumer and medical device class actions.

Daniel Bach is a plaintiff-side class actions litigator, a partner in Siskinds LLP’s Toronto office and a member of the firm’s Board. He represents individuals, governments, asset managers and pension funds in complex securities, product liability, medical device and consumer protection class actions. He has argued before the Supreme Court of Canada, the Ontario Court of Appeal and the British Columbia Court of Appeal. Chambers & Partners recognizes Daniel in its nationwide plaintiff class actions rankings as “ a great overall litigator, an expert in securities and excellent in other fields .” Daniel is admitted in Ontario, British Columbia and New York.

Daniel has acted in some of Canada’s most significant securities class actions. He was counsel in Arctic Glacier and IMAX , the first two cases granted leave under Part XXIII.1 of the Securities Act , both of which also certified common-law misrepresentation claims. He represented the class in Manulife and Sino-Forest , two of the largest securities class actions in Canadian history. Manulife is one of the largest Canadian securities class actions to be granted leave on a contested basis and settled for $69 million on the eve of trial. In Sino-Forest , the class recovered substantial compensation, including a $117 million settlement with Ernst & Young , one of the largest securities class action settlements with an auditor worldwide. Daniel also helped recover more than $100 million for class members in the foreign exchange conspiracy class action.

Daniel’s product liability work focuses on complex mass tort claims. He acts for the class in the certified class action against Juul concerning the marketing and safety of its products. He is lead counsel in class actions against Syngenta relating to its paraquat-containing products, including Gramoxone, which were certified in Québec and nationally . Daniel successfully argued certification for women implanted with transvaginal mesh products and recovered tens of millions of dollars for class members.